Roy Buchanan
Stock Analyst at JMP Securities
(0.71)
# 3,688
Out of 4,711 analysts
43
Total ratings
25%
Success rate
-26.76%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Roy Buchanan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENTA Enanta Pharmaceuticals | Reiterates: Market Outperform | $22 → $21 | $6.28 | +234.39% | 11 | Nov 26, 2024 | |
| HOOK HOOKIPA Pharma | Maintains: Market Outperform | $24 → $7 | $2.02 | +246.53% | 2 | Nov 21, 2024 | |
| ANTX AN2 Therapeutics | Reiterates: Market Outperform | $5 | $1.26 | +296.83% | 5 | Nov 19, 2024 | |
| CVAC CureVac | Reiterates: Market Outperform | $16 | $2.87 | +457.49% | 7 | Sep 16, 2024 | |
| ABUS Arbutus Biopharma | Maintains: Market Outperform | $4 → $5 | $3.21 | +55.76% | 5 | Aug 2, 2024 | |
| INO Inovio Pharmaceuticals | Initiates: Market Outperform | $12 | $1.84 | +552.17% | 1 | Jan 4, 2024 | |
| DVAX Dynavax Technologies | Maintains: Market Outperform | $25 → $27 | $12.72 | +112.26% | 5 | Nov 3, 2023 | |
| ESPR Esperion Therapeutics | Reiterates: Market Outperform | $15 | $2.19 | +584.93% | 1 | Mar 6, 2023 | |
| ARGX argenx SE | Maintains: Market Outperform | $443 → $448 | $623.82 | -28.18% | 2 | Mar 3, 2023 | |
| CRMD CorMedix | Maintains: Market Perform | $14 → $16 | $8.57 | +86.70% | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.48 | - | 2 | Feb 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $420 | $3.22 | +12,943.48% | 1 | Sep 14, 2021 |
Enanta Pharmaceuticals
Nov 26, 2024
Reiterates: Market Outperform
Price Target: $22 → $21
Current: $6.28
Upside: +234.39%
HOOKIPA Pharma
Nov 21, 2024
Maintains: Market Outperform
Price Target: $24 → $7
Current: $2.02
Upside: +246.53%
AN2 Therapeutics
Nov 19, 2024
Reiterates: Market Outperform
Price Target: $5
Current: $1.26
Upside: +296.83%
CureVac
Sep 16, 2024
Reiterates: Market Outperform
Price Target: $16
Current: $2.87
Upside: +457.49%
Arbutus Biopharma
Aug 2, 2024
Maintains: Market Outperform
Price Target: $4 → $5
Current: $3.21
Upside: +55.76%
Inovio Pharmaceuticals
Jan 4, 2024
Initiates: Market Outperform
Price Target: $12
Current: $1.84
Upside: +552.17%
Dynavax Technologies
Nov 3, 2023
Maintains: Market Outperform
Price Target: $25 → $27
Current: $12.72
Upside: +112.26%
Esperion Therapeutics
Mar 6, 2023
Reiterates: Market Outperform
Price Target: $15
Current: $2.19
Upside: +584.93%
argenx SE
Mar 3, 2023
Maintains: Market Outperform
Price Target: $443 → $448
Current: $623.82
Upside: -28.18%
CorMedix
Mar 1, 2023
Maintains: Market Perform
Price Target: $14 → $16
Current: $8.57
Upside: +86.70%
Feb 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $2.48
Upside: -
Sep 14, 2021
Initiates: Market Outperform
Price Target: $420
Current: $3.22
Upside: +12,943.48%